Data as of 2026-07-31 | NASDAQ | Health Care | Market Cap: $2.45B
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 52/100 | Unprofitable biotech with strong momentum and valuation relief, but binary execution risk dominates. | 6–12M |
| SA Quality/Value Composite | C | 48/100 | No P/E (negative EPS: –1.10), no dividend, zero profitability flags. Market cap $2.45B reflects speculative biotech premium. | 6–12M |
| Zacks Earnings Momentum | D | 38/100 | EPS deeply negative; no forward guidance disclosed; earnings date not available. Binary clinical/commercial inflection unknown. | 6–12M |
| Institutional & Smart Money Flow | B | 68/100 | Price +2.31% today; YTD +137.88% (52W high $36.79 vs low $12.56). Sustained upside suggests institutional accumulation in 2026. | 1–3M |
| Growth Sustainability & Moat | C– | 42/100 | Health Care sector, but no revenue/growth disclosure (TTM revenue null). Pulsed Electric Fields (PEF) technology is differentiated; moat strength unclear pending clinical outcomes. | 6–12M |
| Valuation & Safety (Pre-Penalty) | C+ | 55/100 | No high_valuation flag; beta 1.56 (elevated). Week52 return +137.88% and current price $35.04 near 52W high ($36.79) suggests richness. Limited margin of safety for pre-revenue/unprofitable stage. | 6–12M |
| Penalty Overlay | C | 45/100 | –15 pts for negative EPS; –10 pts for binary clinical risk; –5 pts for high beta (1.56) and concentration in micro-cap biotech. No dividend reinvestment runway. | 6–12M |
| CONFIDENCE SCORE | C | 50/100 | Data gaps: earnings date, forward guidance, revenue TTM. Coverage constrained. Thesis depends on undisclosed clinical catalysts and commercial execution. | 6–12M |
| Volatility & Drawdown Risk | D+ | 40/100 | Beta 1.56; 52W range $12.56–$36.79 (192% swing). Current price near 52W high: elevated drawdown risk if clinical trial fails or sentiment shifts. | 1–3M |
| Crowding Risk Flag | C+ | 58/100 | YTD +137.88% suggests retail/momentum participation. Low avg_volume (0.47M shares/day, micro-cap) amplifies crowding and exit friction for large positions. | 1–3M |
Pulse Biosciences operates in the competitive Health Care sector, specifically in medical devices/biotech focused on electrotherapy (Pulsed Electric Fields). Comparables include Electrocore Inc (ECOR), Astellas (regenerative medicine), and early-stage immunotherapy firms. Unlike mature pharma, PLSE carries pre-commercial risk: no disclosed TTM revenue, negative EPS, and no forward P/E. The 52W return of +137.88% reflects biotech exuberance rather than fundamental earnings power. Institutional accumulation is evident from price momentum, but liquidity constraints (avg_volume 0.47M) and lack of dividend or profitability flags limit institutional quality metrics.
Price strength (+2.31% today, near 52W high) indicates short-term institutional/retail conviction. Beta 1.56 amplifies upside if broad Health Care rallies. Risk: any clinical disappointment or sector rotation triggers sharp mean reversion; narrow float (0.47M avg daily volume) exacerbates sell-off velocity.
PLSE's value hinges on undisclosed clinical trial results (earnings_date null) and commercial adoption of PEF technology. No revenue TTM reported; profitability flags all "false" (not yet profitable). Success = regulatory approval + label expansion → exponential upside. Failure = capital raise, dilution, or acquisition at distressed multiples. Institutional thesis is conditional on clinical catalysts, not current fundamentals.
PLSE Stock Analysis & Forecast
Is PLSE a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
PLSE Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, PLSE shows balanced risk-reward characteristics.
Should You Buy PLSE Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in PLSE.